Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OVID THERAPEUTICS INC.

(OVID)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
3.34(c) 3.38(c) 3.4(c) 3.45(c) 3.405 Last
194 659 117 960 100 769 180 059 122 532 Volume
-0.89% +1.20% +0.59% +1.47% -1.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 208 M - -
Net income 2021 134 M - -
Net Debt 2021 - - -
P/E ratio 2021 1,82x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -58,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,05x
Yield 2022 -
Capitalization 234 M 234 M -
Capi. / Sales 2021 1,12x
Capi. / Sales 2022 -
Nbr of Employees 60
Free-Float 70,9%
More Financials
Company
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of... 
More about the company
Ratings of Ovid Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about OVID THERAPEUTICS INC.
09/07OVID THERAPEUTICS : to Present at the H.C. Wainwright 23rd Annual Global Investment Confer..
AQ
08/25OVID THERAPEUTICS : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Ke..
MT
08/18OVID THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
08/17OVID THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Corporate Highlights
AQ
08/16OVID THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Corporate Highlights..
PU
08/16OVID THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/16OVID THERAPEUTICS : Reports Second Quarter 2021 Financial Resultsáand Corporate Highlights
AQ
08/16Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2..
CI
08/16OVID THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/11OVID THERAPEUTICS : Change in Directors or Principal Officers (form 8-K/A)
AQ
08/11Ovid Therapeutics Inc. Appoints Robert Michael Poole as Member of Audit Committee and C..
CI
07/08OVID THERAPEUTICS : Names Chief Operating Officer
MT
07/08OVID THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/08Ovid Therapeutics Inc. Announces Executive and Board Appointments
CI
More news
News in other languages on OVID THERAPEUTICS INC.

- No features available -

More news
Analyst Recommendations on OVID THERAPEUTICS INC.
More recommendations
Chart OVID THERAPEUTICS INC.
Duration : Period :
Ovid Therapeutics Inc. Technical Analysis Chart | OVID | US6904691010 | MarketScreener
Technical analysis trends OVID THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,45 $
Average target price 4,75 $
Spread / Average Target 37,7%
EPS Revisions
Managers and Directors
Jeremy Max Levin Chairman, President & Chief Executive Officer
Jeffrey A. Rona Chief Financial, Accounting & Business Officer
Claude Nicaise Head-Research & Development
Julia Tsai Senior VP-Clinical Development & Medical Affairs
Jason Tardio Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OVID THERAPEUTICS INC.49.35%234
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018